Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cudkowicz, M. E.
Right arrow Articles by Brown, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cudkowicz, M. E.
Right arrow Articles by Brown, R. H., Jr.
Neurology 1999;52:1492
© 1999 American Academy of Neurology
Brief Communications

The pharmacokinetics and pharmacodynamics of Procysteine in amyotrophic lateral sclerosis

M. E. Cudkowicz, MD, MSc, P. M. Sexton, BS, T. Ellis, BA, D. L. Hayden, MA, P. R. Gwilt, PhD, J. Whalen, MD and R. H. Brown, Jr., MD, PhD

From the Day Neuromuscular Research Laboratory (Drs. Cudkowicz and Brown), Massachusetts General Hospital (MGH), Charlestown; the Department of Neurology (Drs. Cudkowicz and Brown, and P.M. Sexton and T. Ellis) and General Clinical Research Center (D.L. Hayden), MGH, Harvard Medical School, Boston, MA; the Department of Pharmaceutical Sciences (P.R. Gwilt), College of Pharmacy, University of Nebraska Medical Center, Omaha, NE; and Transcend Therapeutics, Inc. (Dr Wahlen), Cambridge, MA.

Address correspondence and reprint requests to Dr. Cudkowicz, Department of Neurology, Massachusetts General Hospital, 32 Blossom Street, Rm. ACC 836, Boston, MA 02114; e-mail: Cudkowicz{at}helix.mgh.harvard.edu

In 13 subjects with ALS, we studied the safety and pharmacokinetic properties of Procysteine, a cysteine prodrug that increases levels of intracellular glutathione. We found that oral administration of Procysteine was safe. Procysteine enters CSF after both IV and oral dosing and accumulates to significant levels in CSF. We also observed that CSF levels of glutathione fall dramatically with aging.




This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
L. F. Ferreira, L. A. A. Gilliam, and M. B. Reid
L-2-Oxothiazolidine-4-carboxylate reverses glutathione oxidation and delays fatigue of skeletal muscle in vitro
J Appl Physiol, July 1, 2009; 107(1): 211 - 216.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. K. Niture, C. S. Velu, Q. R. Smith, G.J. Bhat, and K. S. Srivenugopal
Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines
Carcinogenesis, February 1, 2007; 28(2): 378 - 389.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.